Reduced kidney levels of lysophosphatidic acids in rats after chronic administration of aristolochic acid: Its possible protective role in renal fibrosis
- PMID: 28962344
- PMCID: PMC5598376
- DOI: 10.1016/j.toxrep.2015.02.012
Reduced kidney levels of lysophosphatidic acids in rats after chronic administration of aristolochic acid: Its possible protective role in renal fibrosis
Abstract
Aristolochic acid (AA) is considered to be a causative agent for progressive interstitial renal fibrosis, leading to AA nephropathy. Lysophosphatidic acid (LPA) is a mediator in the onset of renal fibrosis. In this study, we analyzed the molecular species of LPA and its precursor lysophospholipids in kidney tissue from rats exposed to AA. Daily intraperitoneal injections of AA for 35 days to rats gave rise to fibrosis in kidney, decreased the kidney levels of LPA, lysophosphatidylserine and lysophosphatidylinositol. In rat renal cell lines (NRK52E and NRK49F), AA-induced cytotoxicity was potentiated by Ki16425, LPA1,3 receptor antagonist. The level of mRNA encording α-smooth muscle actin was significantly increased by AA-treatment only in NRK52E cells, while the mRNA level of collagen III was decreased in both NRK52E and NRK49F cells. These results suggest that endogenous LPA in rat kidney prevents AA-induced renal fibrosis.
Keywords: 18S, ribosomal protein S18; AA, aristolochic acid; AZ, azan Mallory; Aristolochic acid; Chronic kidney disease; Fibrosis; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HE, hematoxylin/eosin; LC–MS/MS, liquid chromatography–tandem mass spectrometry; LPA, lysophosphatidic acid; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; LPG, lysophosphatidylglycerol; LPI, lysophosphatidylinositol; LPL, lysophospholipid; LPS, lysophosphatidylserine; Lysophosphatidic acid; Lysophospholipid; Nephrotoxicity; PLA1, phospholipase A1; PLA2, phospholipase A2; lysoPLD, lysophospholipase D; α-SMA, α-smooth muscle actin.
Figures





Similar articles
-
Reduced rat plasma lysophosphatidylglycerol or lysophosphatidic acid level as a biomarker of aristolochic acid-induced renal and adipose dysfunctions.Life Sci. 2016 Jul 15;157:208-216. doi: 10.1016/j.lfs.2016.06.003. Epub 2016 Jun 4. Life Sci. 2016. PMID: 27267499
-
Lysophosphatidylethanolamine utilizes LPA(1) and CD97 in MDA-MB-231 breast cancer cells.Cell Signal. 2013 Nov;25(11):2147-54. doi: 10.1016/j.cellsig.2013.07.001. Epub 2013 Jul 6. Cell Signal. 2013. PMID: 23838008
-
Altered plasma levels of lysophospholipids in response to adrenalectomy of rats.Prostaglandins Other Lipid Mediat. 2021 Oct;156:106579. doi: 10.1016/j.prostaglandins.2021.106579. Epub 2021 Jul 7. Prostaglandins Other Lipid Mediat. 2021. PMID: 34245896
-
Emerging lysophospholipid mediators, lysophosphatidylserine, lysophosphatidylthreonine, lysophosphatidylethanolamine and lysophosphatidylglycerol.Prostaglandins Other Lipid Mediat. 2009 Sep;89(3-4):135-9. doi: 10.1016/j.prostaglandins.2009.04.009. Epub 2009 May 7. Prostaglandins Other Lipid Mediat. 2009. PMID: 19427394 Review.
-
The actions and metabolism of lysophosphatidylinositol, an endogenous agonist for GPR55.Prostaglandins Other Lipid Mediat. 2013 Dec;107:103-16. doi: 10.1016/j.prostaglandins.2013.05.004. Epub 2013 May 25. Prostaglandins Other Lipid Mediat. 2013. PMID: 23714700 Review.
Cited by
-
Antimicrobial activity and acetylcholinestrase inhibition of novel synthesized pyrimidine derivatives versus Candida albicans trafficking to brain and kidney.Toxicol Rep. 2019 Mar 23;6:262-266. doi: 10.1016/j.toxrep.2019.03.003. eCollection 2019. Toxicol Rep. 2019. PMID: 30976522 Free PMC article.
-
Daily Intake of High-Fat Diet with Lysophosphatidic Acid-Rich Soybean Phospholipids Augments Colon Tumorigenesis in Kyoto Apc Delta Rats.Dig Dis Sci. 2017 Mar;62(3):669-677. doi: 10.1007/s10620-016-4434-5. Epub 2017 Jan 3. Dig Dis Sci. 2017. PMID: 28050783
-
Plasma metabolic profiling analysis of Strychnos nux-vomica Linn. and Tripterygium wilfordii Hook F-induced renal toxicity using metabolomics coupled with UPLC/Q-TOF-MS.Toxicol Res (Camb). 2018 Jul 25;7(6):1153-1163. doi: 10.1039/c8tx00115d. eCollection 2018 Nov 1. Toxicol Res (Camb). 2018. PMID: 30510685 Free PMC article.
References
-
- Grzelczyk A., Gendaszewska-Darmach E. Novel bioactive glycerol-based lysophospholipids: new data – new insight into their function. Biochimie. 2013;95:667–679. - PubMed
-
- Makide K., Kitamura H., Sato Y., Okutani M., Aoki J. Emerging lysophospholipid mediators, lysophosphatidylserine, lysophosphatidylthreonine, lysophosphatidylethanolamine and lysophosphatidylglycerol. Prostaglandins Other Lipid Mediat. 2009;89:135–139. - PubMed
-
- Tokumura A. Metabolic pathways and physiological and pathological significances of lysolipid phosphate mediators. J. Cell. Biochem. 2004;92:869–881. - PubMed
-
- Murph M., Tanaka T., Pang J., Felix E., Liu S., Trost R., Godwin A.K., Newman R., Mills G. Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods Enzymol. 2007;433:1–25. - PubMed
-
- Tsutsumi T., Adachi M., Nikawadori M., Morishige J., Tokumura A. Presence of bioactive lysophosphatidic acid in renal effluent of rats with unilateral ureteral obstruction. Life Sci. 2011;89:195–203. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous